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Abstract
ATP Binding Cassette family efflux proteins ABCB1 and ABCG2 have previously been dem-
onstrated to interact with Tyrosine Kinase Inhibitors (TKIs); however, evidence for the inter-
action of other potentially relevant drug transporters with TKIs is lacking. Through Taqman
transporter array technology we assessed the impact of nilotinib on mRNA expression of
ABC transporters, with ABCC6 identified as a transporter of interest. Additionally, increased
expression of ABCC6 mRNA was observed during in vitro development of nilotinib resis-
tance in BCR-ABL1-expressing cell lines. K562 cells exposed to gradually increasing con-
centrations of nilotinib (to 2 μM) expressed up to 57-fold higher levels of ABCC6 mRNA
when compared with control cells (p = 0.002). Analogous results were observed in nilotinib
resistant K562-Dox cells (up to 33-fold higher levels of ABCC6, p = 0.002). IC50 experi-
ments were conducted on patient mononuclear cells in the absence and presence of three
ABCC6 inhibitors: indomethacin, probenecid and pantoprazole. Results demonstrated that
all three inhibitors significantly reduced nilotinib IC50 (p<0.001) indicating ABCC6 is likely
involved in nilotinib transport. Cell line data confirmed these findings. Similar results were
obtained for dasatinib, but not imatinib. Combined, these studies suggest that nilotinib and
dasatinib are likely substrates of ABCC6 and to our knowledge, this is the first report of
ABCC6 involvement in TKI transport. In addition, ABCC6 overexpression may also contrib-
ute to nilotinib and dasatinib resistance in vitro. With nilotinib and dasatinib now front line
therapy options in the treatment of CML, concomitant administration of ABCC6 inhibitors
may present an attractive option to enhance TKI efficacy.
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Introduction
Chronic Myeloid Leukaemia (CML) is caused by the Breakpoint cluster region-abelson (Bcr-
Abl) oncoprotein, which is effectively inhibited by Tyrosine Kinase Inhibitors (TKIs) such as
imatinib[1] and the second generation inhibitors nilotinib[2] and dasatinib[3]. Resistance to
TKIs can occur due to numerous factors including Bcr-Abl overexpression and most com-
monly because of mutations in the Bcr-Abl kinase domain[4]. However, mounting evidence
emphasises the importance of cellular drug efflux transporters, in particular members of the
ATP-Binding Cassette (ABC) family, and attendant intracellular drug levels in TKI response.
Indeed, recent data has highlighted P-glycoprotein (ABCB1) overexpression as a contributor
to TKI resistance[5] and as a potential biomarker for predicting patient response to imatinib
[6].
Members of the ABC family of transporters are responsible for the extrusion of small mole-
cules, chemotherapeutics and other xenobiotics, including TKIs, from cells[7]. In particular,
ABCB1 and breast cancer resistance protein (BCRP/ABCG2) have previously been implicated
in multidrug resistance and their interaction with TKIs has been thoroughly investigated and
reviewed[8]. More recently the role of ABCC1, ABCC3, ABCC4[9] and ABCA3[10] in TKI
transport and resistance has also been examined. However, to date, no investigations into the
TKI:ABCC6 relationship have been conducted.
ABCC6 (MRP6) belongs to the Multidrug Resistance Protein (MRP) superfamily and is
capable of extruding a wide variety of substrates from cells[11]. ABCC6 bears striking
sequence homology to ABCC1 and is thought to have arisen from a gene duplication[12–14].
While a biological substrate has not yet been elucidated, ABCC6 is known to transport lipo-
philic molecules of negative charge[15, 16] and is primarily expressed at points of drug extru-
sion such as the liver and the kidney[12, 17, 18]. The involvement of ABCC6 in an autosomal
recessive connective tissue disorder, pseudoxanthoma elasticum, is well established despite the
fact that ABCC6 is not expressed in the tissue within which this disease occurs[19, 20].
The involvement of ABCC6 in the transport of, and resistance to, a number of anticancer
agents including etoposide, doxorubicin and daunorubicin has been demonstrated[15, 21].
However, ABCC6 involvement in the transport of other small molecule inhibitors such as
TKIs has not been investigated. Our previous study[22] demonstrated a reduction in niloti-
nib IC50 (based on Bcr-Abl kinase inhibition) in ABCB1 overexpressing K562-Dox cells in
the presence of proton pump inhibitors (PPI) known to inhibit ABCB1[23, 24]. The reduc-
tion observed suggests that PPIs block ABCB1-mediated efflux of nilotinib, increasing the
intracellular concentration and subsequent kinase inhibition thus reducing the IC50.
Intriguingly, the IC50 was also reduced in K562 cells, albeit to a lesser extent, which do not
overexpress ABCB1[22]. These results suggest that an alternate transporter expressed in both
K562-Dox and K562 cells may also be responsible for the efflux of nilotinib leading to the
lowered IC50. PPIs have been previously demonstrated to inhibit ABCC6[15, 23, 25] and
given the overlapping substrate specificities of ABC transporters, further investigations into
the TKI:ABCC6 relationship were warranted. Here we provide the first evidence that ABCC6
may be involved in TKI transport and that overexpression of ABCC6 likely causes resistance
to nilotinib in vitro.
Materials and methods
Ethics statement
This research involved human clinical samples and these correlative studies were approved by
the Royal Adelaide Hospital Research Ethics Committee (RAH protocol number: 070718). All
ABCC6 is involved in nilotinib transport and resistance
PLOS ONE | https://doi.org/10.1371/journal.pone.0192180 January 31, 2018 2 / 18
Competing interests: I have read the journal’s
policy and the authors of this manuscript have the
following competing interests: LNE has no conflict
of interest to declare. DLW receives honoraria and
research funds from Novartis Pharmaceuticals and
is a member of Advisory Boards for Novartis. TPH
receives honoraria and research funds from
Novartis Pharmaceuticals, BMS and Ariad and is a
member of Advisory Boards for Novartis, BMS and
Ariad. However, Novartis, BMS and Ariad had no
role in the design of the study, collection and
analysis of data nor the decision to publish. This
does not alter our adherence to PLOS ONE policies
on sharing data and materials.
samples were collected with informed consent in accordance with the Institutional Ethics
approved protocols and with reference to the Declaration of Helsinki.
Cell lines
BCR-ABL1-expressing cell lines KU812 and K562 were obtained from American Type Culture
Collection (ATCC; Manassas, VA). K562 cells were transfected as described previously and
the resultant K562-ABCG2 cells cultured in 500 μg/mL G418 (Invitrogen, Carlsbad, CA) and
assessed for appropriate ABCG2 expression by quantitative PCR and flow cytometry[26].
K562-Dox cells (ABCB1-overexpressing) were generated after the continuous culture of K562
parental cells in the ABCB1 substrate, doxorubicin. K562-Dox cells now stably express ABCB1
in the absence of doxorubicin (kindly provided by Prof. Leonie Ashman, University of New-
castle, Callaghan, NSW). HepG2 cells were kindly provided by Prof. Andrew Zannettino
(South Australian Health and Medical Research Institute/University of Adelaide, Adelaide,
SA). All suspension cells were cultured as described previously[27]; HepG2 cells were cultured
in Dulbecco’s Modified Eagle Media (DMEM; Sigma). Prior to reculture (1:20 dilution), cells
were trypsinised (0.25%; Sigma), separated by pipetting and resuspended in fresh media
devoid of trypsin. Nilotinib-[5], dasatinib-[28] and imatinib-resistant[28] cell lines were gener-
ated as described previously. Briefly, cell lines were maintained in liquid culture and were
gradually exposed to escalating concentrations of TKI. TKI concentrations were increased
once cells demonstrated tolerance to the current concentration (>80% survival in culture for
>10 days).
Patient cells
Peripheral blood was obtained from de novo chronic phase CML patients before commence-
ment of TKI therapy and mononuclear cells (MNCs) were isolated using Lymphoprep (Axis
Shield, Oslo, Norway) density gradient centrifugation.
TKIs and efflux transporter inhibitors
Imatinib mesylate (Glivec1) and nilotinib (Tasigna1) were provided by Novartis Pharmaceu-
ticals (Basel, Switzerland), dasatinib (Sprycel1) was provided by Bristol-Myers Squibb (Victo-
ria, Australia). Stock solutions of imatinib were prepared at 10 mM in distilled water, sterile
filtered and stored at -80˚C. Stock solutions of nilotinib and dasatinib were prepared at 10 mM
in dimethylsulfoxide (DMSO; Sigma, St Louis, MO) and stored at 4˚C. Verapamil (Royal Ade-
laide Hospital (RAH) Pharmacy) was used at 50 μM from a 2.5 mg/mL stock; pantoprazole
(RAH Pharmacy) was used at 200 μM from a 10 mM stock; indomethacin (Sigma) was used at
100 μM from a 10 mg/mL stock; probenecid (Sigma) was used at 1 mM from a 175 mM stock;
PSC-833 is a Cyclosporin A derivative kindly provided by Novartis Pharmaceuticals and was
used at 10 μM from 8.23 mM stock. The concentrations of inhibitors were chosen based on
specificity of ABC transporter inhibition and previous in vitro experimentation (S1 Table).
p-CRKL determined IC50 and western blotting
BCR-ABL1-expressing cells (2×105 cells) or 2×106 patient mononuclear cells (MNCs) were
incubated for 2 h at 37˚C/5%CO2 with concentrations of nilotinib (NIL) ranging 0–100 μM,
imatinib (IM) ranging 0–100 μM and dasatinib (DAS) ranging 0–5000 nM. Following incuba-
tion, cells were lysed in Laemmli’s buffer[29] before resolution by 12% SDS-PAGE and electro-
phoretic transfer to PVDF membrane (GE Healthcare, Buckinghamshire, UK) at 65 mA
overnight. Western blotting for phosphorylated CT10 regulator of kinase like (p-CRKL) was
ABCC6 is involved in nilotinib transport and resistance
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performed as previously described[30]. IC50 values (IC50NIL, IC50DAS, IC50IM) were deter-
mined as the dose of drug required to reduce p-CRKL levels by 50% and are presented as
mean ± SEM. Western blotting for ABCC6 was performed as described in Supplemental
methods.
Taqman1 array—Human drug transporters
The Taqman1 transporter arrays (Cat# 4414118; Thermo Fisher Scientific, Waltham, MA,
USA) utilise gene-specific primer and probe sets in order to compare gene expression between
treated and untreated samples. The arrays were carried out according to the manufacturer’s
instructions.
Real time quantitative polymerase chain reaction (RQ-PCR). 1×107 intermediately
resistant cells (produced during TKI resistance generation[5]) were stored in TRIzol stabiliza-
tion solution (Invitrogen Life Technologies) at -80˚C. RNA was extracted using the phenol/
chloroform method[31] and cDNA synthesized using random hexamers (GeneWorks, Hind-
marsh, SA, Australia) and Superscript II reverse transcriptase (Invitrogen Life Technologies).
Primers were designed using Primer Express software v2.0 (Applied Biosystems, Foster City,
CA, USA), and sequences were as described in Supplemental methods. Amplification was per-
formed using RT2 real-time SYBR Green/ROX PCR Master Mix (SuperArray Bioscience,
Frederick, MD, USA) on a RotorGene real time PCR machine (Corbett Research, San Fran-
cisco, CA, USA). Results were analysed using Rotor-Gene 6000 Series software (Corbett
Research) and the relative expression levels of the transporters were calculated by the compara-
tive Ct method using the 2ΔΔCt formula to achieve results for relative quantification. The
ABCC6 control cell line HepG2 was used as a calibrator and all samples were normalized to
the house keeping gene BCR.
Statistics
Statistical tests were performed using the GraphPad Prism 6 statistical software (GraphPad
Prism Inc, La Jolla, CA, USA). Normality tests were performed on each data set using the
D’Agostino & Pearson omnibus normality test. The Mann-Whitney Rank Sum or the Stu-
dent’s t-test were used to determine differences between experimental groups depending on
whether the data sets failed or passed the normality test, respectively. Differences were consid-
ered to be statistically significant when the probability value (p-value) was <0.05.
Results
ABCB1 inhibition does not significantly affect nilotinib-mediated kinase
inhibition in patient mononuclear cells
The prognostic value of monitoring early alterations in ABCB1mRNA expression levels in
CML patient cells in order to predict patient response to imatinib has recently been described
[6]. ABCB1 overexpression has also been implicated in nilotinib, imatinib and dasatinib resis-
tance development in vitro[5]. For this reason, the effect of three ABCB1 inhibitors (pantopra-
zole, verapamil, PSC-833, S1 Table) on IC50NIL was assessed in patient MNCs prior to the start
of TKI therapy. The IC50 assay is a surrogate for sensitivity to Bcr-Abl kinase inhibition and it
was expected that if ABCB1 is involved in the efflux of nilotinib from patient MNCs, inhibition
of this transporter should increase concentrations of intracellular nilotinib resulting in a
reduction in IC50NIL. Unexpectedly, a significant decrease in IC50NIL was observed only
in those cells incubated in the presence of 200 μM pantoprazole (Fig 1A, S1A Fig): 41 nM ver-
sus 71 nM in control cells cultured in the absence of inhibitors (p<0.001). The addition of
ABCC6 is involved in nilotinib transport and resistance
PLOS ONE | https://doi.org/10.1371/journal.pone.0192180 January 31, 2018 4 / 18
Fig 1. Chemical inhibition of ABCC6 but not ABCB1 increases the efficacy of nilotinib in patient MNCs. p-CRKL determined IC50NIL was
determined via incubating patient MNCs with increasing concentrations of nilotinib in the absence and presence of (A) three ABCB1 inhibitors:
PSC-833, verapamil and pantoprazole and (B) three ABCC6 inhibitors: pantoprazole, indomethacin, probenecid. CRKL western blotting was
performed to determine the concentration of nilotinib required for 50% Bcr-Abl kinase inhibition (IC50NIL). Representative western blots are
shown in S1 Fig. The box plots depict the median, the upper 25th and the lower 75th percentiles while the whiskers encompass the 10th and 90th
ABCC6 is involved in nilotinib transport and resistance
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10 μM PSC-833 and 50 μM verapamil had no effect on IC50NIL: 76 nM and 80 nM respectively
(p>0.05;).
Nilotinib may be effluxed by other previously unidentified ABC
transporters
We have also previously observed a significant decrease in IC50NIL in BCR-ABL1+ cell lines in
the presence of pantoprazole and to a lesser extent esomeprazole (dual ABCB1/ABCG2 inhibi-
tors)[22]. Interestingly, comparable results were observed in two different cells lines regardless
of ABCB1 expression: K562-Dox cells (ABCB1-overexpressing) and the parental K562 cells
(negligible ABCB1/ABCG2). Thus, for the current study we investigated the effect of different
concentrations of pantoprazole in a further two cell lines: KU812 (negligible ABCB1/ABCG2)
and K562-ABCG2 cells (ABCG2-overexpressing)[27]. Results demonstrated a significant
reduction in IC50NIL in the presence of pantoprazole in all cell lines regardless of the ABCB1/
ABCG2 expression status that was proportionate to the dose of pantoprazole (Table 1). The
greatest reduction occurred in K562 cells (71% reduction in the presence of 500 μM pantopra-
zole, p<0.001), which express negligible levels of ABCB1 and ABCG2. These data, combined
with observations in patient MNCs, suggest there may be other clinically relevant ABC efflux
transporter/s that are involved in nilotinib transport and are inhibitable by pantoprazole.
percentiles. Statistical analyses were performed using Student’s t-test with statistically significant p-values denoted by asterisks ( p<0.001).
NIL = nilotinib.
https://doi.org/10.1371/journal.pone.0192180.g001
Table 1. The effect of increasing concentrations of pantoprazole on IC50NIL in BCR-ABL1+ cell lines.
Cell Line Transporter Expression IC50NIL (nM) Decrease (%) p-value
ABCB1 ABCG2
K562
Control (n = 6) ✘ ✘ 388
+50 μM PP (n = 3) ✘ ✘ 254 34 p = 0.012
+200 μM PP (n = 5) ✘ ✘ 217 44 p = 0.002
+500 μM PP (n = 4) ✘ ✘ 114 71 p = 0.0002
K562-Dox
Control (n = 5) ✔ ✘ 463
+50 μM PP (n = 3) ✔ ✘ 202 56 p = 0.021
+200 μM PP (n = 4) ✔ ✘ 201 57 p = 0.010
+500 μM PP (n = 3) ✔ ✘ 145 69 p = 0.010
K562-ABCG2
Control (n = 6) ✘ ✔ 261
+50 μM PP (n = 5) ✘ ✔ 122 53 p = 0.007
+100 μM PP (n = 5) ✘ ✔ 157 40 p = 0.041
+200 μM PP (n = 5) ✘ ✔ 120 54 p = 0.011
KU812
Control (n = 5) ✘ ✘ 305
+50 μM PP (n = 5) ✘ ✘ 149 51 p = 0.010
+100 μM PP (n = 5) ✘ ✘ 146 52 p = 0.011
+250 μM PP (n = 5) ✘ ✘ 117 62 p = 0.004
Statistical analyses were performed using Student’s t-test; NIL = nilotinib, PP = pantoprazole.
https://doi.org/10.1371/journal.pone.0192180.t001
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Exposure to nilotinib increases expression of ABCC6 in vitro
Previous studies have demonstrated that incubation with various cytotoxic agents results in
increased mRNA expression of transporters known to be relevant for those drugs[32, 33].
Thus, in order to identify other candidate transporters potentially involved in the efflux of
nilotinib, commercially available Taqman1 transporter array plates were used to assess
mRNA expression levels in BCR-ABL1+ K562 and KU812 cells incubated overnight in the
absence and presence of 75 nM and 100 nM nilotinib respectively. Additionally, K562 cells
that had been cultured long term in nilotinib[5] were also assessed for alterations in trans-
porter expression compared with control cells (Fig 2A). Results demonstrated a consistent
increase in ABCC6mRNA in response to nilotinib exposure, highlighting ABCC6 as a likely
candidate for nilotinib transport. In K562 and KU812 cells exposed transiently to nilotinib,
ABCC6mRNA levels were increased 9.7- and 9.5-fold respectively compared with cells incu-
bated in the absence of nilotinib; in K562 cells exposed long term to 300 nM and 2 μM niloti-
nib, ABCC6mRNA levels increased up to 64-fold compared with control cells (Fig 2A). These
results were validated through assessment of ABCC6mRNA levels over the course of nilotinib
resistance generation in K562 and K562-Dox intermediately resistant cells[5]. ABCC6mRNA
levels increased significantly at the onset of nilotinib resistance in both cell lines (Fig 2B and
2C). In K562 cells, levels peaked at 57-fold greater in the 300 nM NIL cells compared with con-
trol cells (p = 0.002) while in K562-Dox cells the 1 μM NIL cells demonstrated 33-fold greater
ABCC6mRNA levels compared with control cells (p = 0.002).
ABCC6 protein is expressed in BCR-ABL1+ cell lines and ABCC6
inhibition increases efficacy of nilotinib in vitro
Before ABCC6 could be validated as a likely transporter of nilotinib, confirmation was
required of a) ABCC6 expression in BCR-ABL1+ cell lines and b) pantoprazole-mediated inhi-
bition of ABCC6. Indeed, all four cell lines expressed detectable levels of ABCC6 (Fig 3A) and
a comprehensive literature search for inhibitor cross reactivity revealed pantoprazole likely
inhibits ABCC6 (S1 Table). Thus, the ABCC6:TKI interaction warranted further investigation
in cell lines and patient MNCs. Confoundingly, promiscuity in transporter inhibition for
drugs such as pantoprazole make it difficult to isolate the transporter upon which a given
inhibitor is acting. For this reason, a panel of ABCC6 inhibitors, with overlapping inhibition
profiles, was used to ascertain the involvement of ABCC6 in the transport of nilotinib. This
approach that has been successfully employed previously to eliminate transporters unlikely to
interact with imatinib[34].
IC50NIL experiments were repeated in the presence of pantoprazole as well as two addi-
tional ABCC6 inhibitors: indomethacin and probenecid. The addition of all inhibitors signifi-
cantly reduced IC50NIL in all cell lines studied (Fig 3B–3D, S2 Fig). In KU812 cells: IC50NIL
was reduced from 325 nM to 117 nM (p<0.001), to 154 nM (p<0.01) and to 171 nM (p<0.05)
in the presence of pantoprazole, indomethacin and probenecid respectively. Similar results
were observed in K562, K562-Dox and K562-ABCG2 cells. The relevance of ABCC6-mediated
transport of nilotinib was then investigated in the patient setting (Fig 1B, S1B Fig). Impor-
tantly, when patient MNCs were cultured in the presence of indomethacin or probenecid, a
reduction in IC50NIL was observed, confirming observations made in the presence of panto-
prazole as well as those made in cell lines. ABCC6 inhibition reduced IC50NIL from 71 nM in
cells incubated in the absence of inhibitors to 38 nM and 28 nM in cells cultured with indo-
methacin and probenecid respectively (p<0.001). Taken together, these results indicate the
likely role of ABCC6 in the transport of nilotinib.
ABCC6 is involved in nilotinib transport and resistance
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Fig 2. ABCB1 and ABCC6mRNA levels increase in concert during development of nilotinib resistance in
BCR-ABL1+ cell lines. (A) Expression levels of ABCC6mRNA were assessed by Taqman1 transporter array in K562
and KU812 cells exposed transiently (overnight, O/N) and long term to nilotinib Expression levels of ABCC6 and
ABCB1mRNA were assessed in (B) K562 and (C) K562-Dox cells gradually made resistant to nilotinib by exposure to
increasing concentrations over time. (A) ABCC6 levels were normalized to selected control genes (as determined by
ABCC6 is involved in nilotinib transport and resistance
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ABCC6 inhibition increases the efficacy of dasatinib, but not imatinib, in
both BCR-ABL1+ cell lines and patient MNCs
Analogous experiments testing the effect of ABCC6 inhibitors on the efficacy of dasatinib and
imatinib were performed in BCR-ABL1+ cell lines. Data demonstrated that the addition of
pantoprazole, indomethacin or probenecid resulted in a significant reduction in IC50DAS in all
cell lines tested (p<0.05; Fig 4A–4D). No effect of ABCC6 inhibitors on IC50IM was observed
(Fig 4E and 4F) denoting imatinib as an unlikely substrate for ABCC6. The role of ABCC6 in
the efflux of dasatinib and imatinib from CML patient MNCs was also investigated (Fig 5A,
S5A Fig). Again, IC50 experiments were performed in the absence and presence of pantopra-
zole, indomethacin and probenecid. Results confirmed those observed in cell lines and demon-
strated a significant decrease in IC50DAS in the presence of all three inhibitors: IC50DAS was
reduced from 4.3 nM in the absence of inhibitor to 3.2 nM (p = 0.014), 2.5 nM (p<0.001) and
2.2 nM (p<0.001) in the presence of pantoprazole, indomethacin and probenecid respectively.
In contrast, equivalent experiments investigating the effect of ABCC6 inhibition on imatinib
efficacy in CML patient MNCs demonstrated no change in IC50IM in the absence or presence
of ABCC6 inhibition (Fig 5B, S5B Fig): IC50IM in the absence of inhibitor = 0.96 μM versus
1 μM, 1 μM and 1.1 μM (p>0.05) in the presence of pantoprazole, indomethacin and probene-
cid respectively. Thus, while ABCC6 inhibition significantly increases the efficacy of dasatinib
presumably through reduced dasatinib efflux, it is unlikely ABCC6 plays a role in the transport
of imatinib in patient MNCs.
ABCC6 is the most important transporter in development of nilotinib
resistance and contributes to dasatinib resistance in vitro
We have previously examined ABCB1mRNA expression in cells made resistant to nilotinib[5]
and now we compare this with ABCC6mRNA expression. Data suggest that ABCB1 and
ABCC6 work in concert during the development of nilotinib resistance (Fig 2). Interestingly,
ABCC6 overexpression appears to contribute to nilotinib resistance to a greater extent than
ABCB1. In K562 cells, ABCC6 expression levels increased in concordance with exposure to
increasing nilotinib concentrations (up to 57-fold higher than expression levels in control cells,
p<0.001) and remained high for the duration of nilotinib dose escalation (Fig 2B). In contrast,
while ABCB1 levels increased initially, 5-fold greater levels were observed in cells resistant to 140
nM nilotinib compared with control cells (p<0.001), continued exposure to escalating nilotinib
concentrations resulted in reduction of ABCB1 to levels comparable with those observed in con-
trol cells (Fig 2B). Similar results were observed during the generation of nilotinib resistance in
K562-Dox cells (Fig 2C). Comparable results were obtained for dasatinib resistant cells but not
imatinib resistant cells supporting IC50 data and a dasatinib:ABCC6 interaction (S6 Fig).
Discussion
ABCC6 is primarily expressed in the liver and kidney[12, 17, 18] and confers resistance to a
number of anti-cancer agents[15]. While it presents a likely and novel candidate to function as
Thermo Fisher Scientific DataAssist Software v1.0) and fold change in cells cultured in the presence of nilotinib
calculated relative to cells cultured in the absence of nilotinib. (B-C) ABCC6 and ABCB1 levels were normalized to the
housekeeping gene BCR and fold change in resistance intermediates calculated relative to control cells (control cell fold
change was set at 1). The mRNA expression represents the mean of six independent experiments performed in
triplicate. Statistical analyses were performed using Student’s t-test. Statistically significant p-values are denoted by
asterisks (ABCC6) and carets (ABCB1)  p<0.05;  p<0.01;  p<0.001). Error bars represent SEM. NIL = nilotinib;
RES = resistant.
https://doi.org/10.1371/journal.pone.0192180.g002
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a TKI transporter, the ABCC6:TKI relationship has not previously been studied. Here we dem-
onstrate for the first time, that ABCC6 plays a role in the export of nilotinib and dasatinib
from CML patient MNCs and that ABCC6 inhibition increases the efficacy of these TKIs.
Importantly, ABCC6 inhibition had no effect on imatinib efficacy indicating an unlikely role
Fig 3. Chemical inhibition of ABCC6 increases the efficacy of nilotinib in BCR-ABL1+ cell lines. (A) Expression levels of ABCC6 protein were assessed
in K562, K562-Dox, K562-ABCG2 and KU812 BCR-ABL1+ cell lines. The western blot analyses are representative and the corresponding densitometry
analysis represents the mean of three experiments. HepG2 cells were used as a positive control and protein levels were normalised to β-ACTIN. HepG2 cells
express two splice variants of ABCC6; BCR-ABL1+ cell lines express the N-glycosylated isoform only. (B) K562 (C) K562-Dox (D) K562-ABCG2 and (E)
KU812 cells were incubated with increasing concentrations of nilotinib in the absence and presence of three ABCC6 inhibitors (200 μM pantoprazole,
100 μM indomethacin, 1 mM probenecid). CRKL western blotting was performed to determine the concentration of TKI required for 50% Bcr-Abl kinase
inhibition (IC50NIL). Two K562 control bars are shown as experiments in the two groups were performed months apart. Error bars represent SEM.
Representative western blots are shown in S2 Fig. NIL = nilotinib; PP = pantoprazole; Indo = Indomethacin; Pro = probenecid.
https://doi.org/10.1371/journal.pone.0192180.g003
ABCC6 is involved in nilotinib transport and resistance
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Fig 4. Chemical inhibition of ABCC6 increases the efficacy of dasatinib but not imatinib in BCR-ABL1+ cell lines.
(A,E) K562 (B,F) K562-Dox (C,G) K562-ABCG2 and (D,H) KU812 cells were incubated with the indicated
concentrations of (A-D) dasatinib and (E-H) imatinib in the absence and presence of three ABCC6 inhibitors (200 μM
pantoprazole, 100 μM indomethacin, 1 mM probenecid). CRKL western blotting was performed to determine the
concentration of TKI required for 50% Bcr-Abl kinase inhibition (IC50). Error bars represent SEM. Representative
ABCC6 is involved in nilotinib transport and resistance
PLOS ONE | https://doi.org/10.1371/journal.pone.0192180 January 31, 2018 11 / 18
for this transporter in imatinib efflux and confirming the specificity of the ABCC6:nilotinib/
dasatinib interaction. ABCC6 is known to transport substrates anionic in nature[35]. Imatinib
predominantly exists in vivo as a cation owing to the large degree of protonation at physiologi-
cal pH[36]. In contrast, nilotinib and dasatinib exist more often as anions and nilotinib is
transported by a number of Organic Anion Transporters (OATs)[37]. These observations
make nilotinib and dasatinib likely ABCC6 substrates, a notion supported by the data pre-
sented here.
ABCB1 has previously been implicated as an important transporter of TKIs in BCR-ABL1
+ cell lines[8] and increases in expression during development of resistance to nilotinib have
been observed in vitro[5, 38, 39]. In this study we investigated the impact of ABCB1 inhibitors
on nilotinib-mediated Bcr-Abl kinase inhibition (IC50NIL). If nilotinib is indeed transported
by ABCB1 one would expect the IC50NIL to decrease in the presence of ABCB1 inhibition.
However, results were unexpected with only pantoprazole demonstrating a significant effect
on IC50NIL in patient MNCs. There are two possible explanations for this; firstly, nilotinib is
not transported by ABCB1, however, this seems unlikely given the large volume of in vitro data
supporting ABCB1 transport. Alternatively, ABCB1 may not be a relevant transporter in
patient MNCs. This hypothesis is more plausible given the low expression levels of ABCB1
protein our laboratory has observed in routine screening of de novo CML patients (unpub-
lished data). However, high expression of ABCB1 has been demonstrated in primitive CD34
+CD38– and CD34+CD38+ CML cells[40] as well as cells at the blood-brain barrier[41].
Thus, ABCB1-mediated TKI efflux may predominantly occur in primitive subsets of cells and
in cells at blood-tissue barriers (CNS, brain, testes) enhancing exclusion of TKIs and providing
a reservoir of residual leukaemic cells. In contrast, ABCC6-mediated transport of nilotinib
may be more relevant in the MNC populations present in patients prior to receiving TKI
therapy.
In addition to providing evidence that ABCC6 is the predominant transporter of nilotinib
in patient MNCs, this study also suggests that ABCC6 is the most important transporter
involved in development of nilotinib resistance. Previous studies have demonstrated that, upon
exposure to certain xenobiotics, cells increase mRNA expression of transporters known to
interact with the substrate under investigation[32, 33, 42–44]. ABCC6mRNA expression was
investigated in two BCR-ABL1+ cell lines during development of nilotinib resistance in vitro
with expression increasing concomitantly upon exposure to escalating nilotinib concentrations
and remaining high. In contrast, increased ABCB1 expression appears to provide the initial
platform required for development of additional mechanisms of resistance to TKIs in vitro,
including the overexpression of ABCC6 presented here. This hypothesis is supported by previ-
ous research in both cell lines[5] and primary patient cells[6]. A similar pattern of transporter
expression was observed in BCR-ABL1+ cell lines made resistant to dasatinib where increased
ABCB1was followed by persistent overexpression of ABCC6. Increases in ABCC6 expression
did not occur during development of imatinib resistance in the cell line models here.
The results presented here offer an explanation for the clinical observation that the con-
comitant use of a PPI such as pantoprazole results in a better response to nilotinib in CML
patients[45]. Those patients receiving the standard 300 mg twice daily (BID) nilotinib therapy
who also received a PPI for >50% of their time undergoing nilotinib therapy demonstrated
higher rates of Major Molecular Response (MMR, <0.1% BCR-ABL1IS) at 12 months com-
pared with those patients who received nilotinib alone. The difference in MMR rates was even
western blots are shown in S3 and S4 Figs. IM = imatinib; DAS = dasatinib; PP = pantoprazole; Indo = Indomethacin;
Pro = probenecid.
https://doi.org/10.1371/journal.pone.0192180.g004
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Fig 5. Chemical inhibition of ABCC6 increases the efficacy of dasatinib but not imatinib in patient MNCs. p-CRKL determined IC50 was
determined via incubating patient MNCs with increasing concentrations of (A) dasatinib and (B) imatinib in the absence and presence of three
ABCC6 inhibitors: pantoprazole, indomethacin, probenecid. CRKL western blotting was performed to determine the concentration of TKI
required for 50% Bcr-Abl kinase inhibition (IC50). Representative western blots are shown in S3 and S4 Figs. The box plots depict the median, the
upper 25th and the lower 75th percentiles while the whiskers encompass the 10th and 90th percentiles. Statistical analyses were performed using
Student’s t-test with statistically p-values denoted by asterisks ( p<0.01;  p<0.001). IM = imatinib. DAS = dasatinib.
https://doi.org/10.1371/journal.pone.0192180.g005
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greater in patients receiving a 400 mg BID dose. While superior rates of MMR were observed
in both newly diagnosed patients as well as imatinib-resistant or–intolerant patients receiving
PPI co-treatment, the differences failed to reach statistical significance. This was likely due to
the small sample sizes in each of the patient cohorts. Importantly, our data support those find-
ings and provide justification for a standardized trial comparing the long-term responses to
nilotinib with and without co-administration of an ABCC6 inhibitor such as pantoprazole.
Taken together these data support ABCC6-mediated transport of nilotinib and dasatinib in
cell lines as well as in patient MNCs. In vitro evidence also suggests that ABCC6 overexpres-
sion may play a role in development of resistance to both nilotinib and dasatinib although the
contribution to resistance in the clinical setting remains to be elucidated. Concomitant admin-
istration of inhibitors of ABC transporters have previously been demonstrated to increase the
efficacy of various cytotoxic agents in vitro[46, 47]. Importantly, simultaneous administration
of pantoprazole in patients receiving nilotinib therapy has been investigated with no adverse
effect on TKI efficacy described[22, 45]; indeed increased rates of MMR were observed. In
conclusion, our data suggest that ABCC6 functions as a novel efflux transporter of nilotinib
and dasatinib, but not imatinib in BCR-ABL+ cell lines as well as patient MNCs. The difference
in ABCC6 affinity we observed between first and second generation inhibitors could poten-
tially be due to the cationic and anionic forms in which imatinib and nilotinib/dasatinib exist
at physiological pH. Finally, inhibition of ABCC6 significantly decreases IC50NIL and IC50DAS
in patient MNCs, most likely due to an increase in intracellular TKI concentrations. The data
presented here provide a strong rationale for a trial investigating the concomitant use of panto-
prazole with nilotinib and dasatinib in the treatment of de novo CP-CML patients to enhance
the retention of these TKIs in the target MNC population.
Supporting information
S1 Fig. Chemical inhibition of ABCC6 but not ABCB1 increases the efficacy of nilotinib in
patient MNCs. p-CRKL determined IC50NIL was determined via incubating patient MNCs
with the indicated concentrations of nilotinib in the absence and presence of a) three ABCB1
inhibitors: PSC-833, verapamil and pantoprazole and b) three ABCC6 inhibitors: pantopra-
zole, indomethacin, probenecid. CRKL western blotting was performed to determine the con-
centration of nilotinib required for 50% Bcr-Abl kinase inhibition (IC50NIL). The western blots
depict one patient and are representative of typical results. NIL = nilotinib; Ver = verapamil;
PP = pantoprazole; Indo = Indomethacin; Pro = probenecid.
(TIF)
S2 Fig. Chemical inhibition of ABCC6 increases the efficacy of nilotinib in BCR-ABL1
+ cell lines. p-CRKL determined IC50NIL was determined via incubating a) K562 b)
K562-Dox c) K562-ABCG2 and d) KU812 cells with the indicated concentrations of nilotinib
in the absence and presence of three ABCC6 inhibitors (200 μM pantoprazole, 100 μM indo-
methacin, 1 mM probenecid). CRKL western blotting was performed to determine the con-
centration of TKI required for 50% Bcr-Abl kinase inhibition (IC50NIL). The western blots
are representative of typical results. The arrows depict approximate nilotinib concentration
required for achievement of equal levels of CRKL and p-CRKL proteins. NIL = nilotinib.
PP = pantoprazole; Indo = Indomethacin; Pro = probenecid.
(TIF)
S3 Fig. Chemical inhibition of ABCC6 increases the efficacy of dasatinib in BCR-ABL1
+ cell lines. p-CRKL determined IC50DAS was determined via incubating a) K562 b)
K562-Dox c) K562-ABCG2 and d) KU812 cells with the indicated concentrations of dasatinib
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in the absence and presence of three ABCC6 inhibitors (200 μM pantoprazole, 100 μM indo-
methacin, 1 mM probenecid). CRKL western blotting was performed to determine the con-
centration of TKI required for 50% Bcr-Abl kinase inhibition (IC50DAS). The western blots
are representative of typical results. The arrows depict approximate dasatinib concentration
required for achievement of equal levels of CRKL and p-CRKL proteins. DAS = dasatinib;
PP = pantoprazole; Indo = Indomethacin; Pro = probenecid.
(TIF)
S4 Fig. Chemical inhibition of ABCC6 has no effect on the efficacy of imatinib in BCR-
ABL1+ cell lines. p-CRKL determined IC50IM was determined via incubating a) K562 b)
K562-Dox c) K562-ABCG2 and d) KU812 cells with the indicated concentrations of imatinib
in the absence and presence of three ABCC6 inhibitors (200 μM pantoprazole, 100 μM indo-
methacin, 1 mM probenecid). CRKL western blotting was performed to determine the concen-
tration of TKI required for 50% Bcr-Abl kinase inhibition (IC50IM). The western blot analyses
are representative of typical results. The arrows depict approximate imatinib concentration
required for achievement of equal levels of CRKL and p-CRKL proteins. IM = imatinib;
PP = pantoprazole; Indo = Indomethacin; Pro = probenecid.
(TIF)
S5 Fig. Chemical inhibition of ABCC6 increases the efficacy of dasatinib but not imatinib
in patient MNCs. p-CRKL determined IC50IM and IC50DAS were determined via incubating
patient MNCs with the indicated concentrations of a) dasatinib and b) imatinib in the absence
and presence of three ABCC6 inhibitors: pantoprazole, indomethacin, probenecid. CRKL
western blotting was performed to determine the concentration of imatinib or dasatinib
required for 50% Bcr-Abl kinase inhibition (IC50). The western blots depict one patient and
are representative of typical results. DAS = dasatinib; IM = imatinib; PP = pantoprazole;
Indo = Indomethacin; Pro = probenecid.
(TIF)
S6 Fig. ABCB1 and ABCC6 mRNA levels increase in concert during development of dasati-
nib resistance in BCR-ABL1+ cell lines. Expression levels of ABCC6 and ABCB1mRNA were
assessed in a) K562 b-c) K562-Dox cells and c) KU812 gradually made resistant to a-b) dasati-
nib or c-d) imatinib by exposure to increasing concentrations of TKI over time. ABCC6 and
ABCB1 levels were normalized to the housekeeping gene GUSB and fold change in resistance
intermediates calculated relative to control cells (control cell fold change was set at 1). The
mRNA expression represents a single experiment performed in triplicate. DAS = dasatinib;
IM = imatinib; RES = resistant.
(TIF)
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